Tag Archives | genomics personalized medicine

Large Cap Biopharmaceuticals Winners and Losers 2015-16: Which Stocks Can Outperform the ETFs in 2016?… Part 1

Where is the Growth Potential in Large Cap Biopharmaceutical Companies? Caution: Risk Aversion Remains High Investing in biotech stocks ain’t getting easier. The sector is underperforming the market by 16% YTD, sentiment has been burned by concerns about drug pricing and even the spectre of a FED rate rise, with potentially less available equity funding, […]

Continue Reading 0

Rayno Dx and Tools: Abbott (ABT) Buys Alere (ALR) For $5.8B Expanding Point-of-Care Diagnostics Platforms

Abbott Laboratories Acquires Alere (ALR) -Stock Soars 45% At Market Opening Alere Product Line Offers Synergies and Boosts Global Diagnostics Presence 2015 Revenues of Alere Are Estimated in $2.5B Range So Deal is About 2.3X Sales Alere (ALR) has a broad-based product line in rapid point-of-care diagnostics with tests for infectious disease such as influenza […]

Continue Reading 0

Biotech Bear Market Rally on Hold: Lackluster Tape for Week One 2016…Update-1

Update-1… 3P EST –Biotechs Sink Further XBI Down 5%, IBB down 2.34% Green stocks are hard to find: GILD, HOLX, REGN Biotech Bear Market: Lackluster Tape Says Wait Until Next Week For Market Direction Year-End Rally Fizzles in New Year Biotech stocks (IBB) are off 5% from year-end 2015 highs and up only 6.73% from […]

Continue Reading 0

Biotech Winners 2015: Rayno Mid Caps Were Up 29.6%

Biotech Winners 2015: Rayno Mid-Cap Performance Rayno Biopharmaceutical Portfolios beat the bellwether IBB in 2015 . We previously reviewed the Rayno Small Cap Portfolio which was up 38.1% in Q4 2015  and the Mid-Caps also beat despite a big loss by Clovis Oncology after the FDA required more data on its lung cancer drug. The […]

Continue Reading 0

2015 Life Science Sector Review As Biopharma Rally Fades

Biopharma Rally On Hold This is not a good week for trading. Portfolio managers are re-jiggering positions so you may not see the trends correctly. Today there was much more red than green.Many biotech stocks started rallying off the bottom in October then again around December 11. There are many cross currents in the market […]

Continue Reading 0

Healthcare Stocks Will be Under Fire in 2016; Biotech Rally Needs Help…Update-2

Tradeable Intermediate Bottom Today  12:36P… 12/15 GILD 102.8,IBB 331 Update at Close Update…Sunday 12/13/15…Grim Outlook…Risk Off The market sunk further Friday afternoon after 3p for a NASDAQ close at 4933 off 2.33% (up 4.17% YTD) for the day.Biotech ETFS were hit even harder with the IBB down 2.89% (up 5.45% YTD) and the XBI down […]

Continue Reading 0

Biotech Rally Gains Momentum…Update-1

Update-1 Rayno Recap for week of 11/20/15 IBB up 3.04%, XBI  up 1.92%,  XLV up 2.82% Notable Small Cap Winners Curis (CRIS) up 4.13%, Fibrocell Sciences (FCSC) up 3.42%, Geron (GERN) up 4.82%, Ignyta (RXDX) up 37.39%, and Ocera Therapeutics (OCRX) up 5.31%. Notable Rayno Dx and Tools Winners Cepheid (CPHD) up 6.45%, Illumina (ILMN) […]

Continue Reading 0

Biotech Rally Underway Trying to Overcome Gloomy Macro Data…Update-1

Update 11/16 PM Biotech Rally Underperforms Energy up 2.99% and Telecom up 1.81% The S&P and Dow rallied past Paris attack and terrorism concerns after an early morning stall. Biotechs underperformed weighed down by the Clovis Oncology (CLVS) NDA delay. The IBB was up 0.39% in a choppy session. Among the losers were mid-caps awaiting […]

Continue Reading 0

Rayno Tools and Molecular Diagnostics: Looking For Value

Looking for Value in a Slow Growth Market Life Science stocks took a big hit over the past summer and many have not fully recovered.The important metric to watch is sales growth because many of the smaller cap companies are still lagging in earnings growth so the PE tells you very little. The major technology […]

Continue Reading 0

Choppy Action Today in Biotech Stocks But Buyers Are Out There…Update-1

October 21  Update 9:45a EDT NASDAQ up 0.4% IBB up 1.57% 1:45p EDT Biotech Thrashing Continues-High Fliers Hit Hardest Healthcare stocks remain under attack with the XLV down 1.5% and the IBB down 1.6%.Healthcare is the sector loser down 2% while the Industrials are up slightly. Large cap Biogen (BIIB) is still up 2.5% after […]

Continue Reading 0

BIO Investor Forum 2015 Next Week…Update

10/21 I will be posting articles from the Meeting later this week and next week. 2015 Bio Investor Forum October 20-21, 2015 We will be attending the Bio Investor Forum 2015 in San Francisco next week. Various panels will cover important biotherapy topics such as oncology trends, precision medicine and full genome analysis and valuation […]

Continue Reading 0

Biotech Stocks Crushed on Drug Pricing Issue: Caution…Update-1

Update-1… 9/22/15 …Biotech Stocks Trade Down Another Day  Biotech stocks were weak tracking NASDAQ which was down 1.5%. The IBB was down 1.49% to $335.40 flat over one month and up 10.57% YTD. The August low was $325 and the IBB is 16% off July 20 highs. The small cap weighted XBI was down 2.29% […]

Continue Reading 0

Notes from BIO 2015 #1 Recap and Biotechnology Trends-M&A, Precision Medicine

Updated 6/25 Precision Medicine -Novel Prevention and Treatment Strategies Lead The Way A New Initiative on Precision Medicine — NEJM Over 15,000 attended BIO 2015 in Philadelphia including 1100 companies and more than 30 nations. The Exhibits and Partnering meetings were excellent opportunities for networking and dealmaking as usual. We attended several of the sessions and […]

Continue Reading 0

Biotech Stocks Hit New Highs-Large Caps Lead The Way…Update-2 June 25

Update -2 … June 25… IBB off all time high of 379.97 SCOTUS opinion in favor of ACA (ObamaCare) is favorable to hospital stocks and positive for HC sector overall as we have assumed since 2010. The XLV Health Care Select SPDR ETF is up 11.25% YTD and 162.5% over five years. The bull market […]

Continue Reading 0

Slower Growth in Diagnostics Stocks Except for NexGen Sequencing and Molecular

New technologies in diagnostics and tools are driving growth: NexGen sequencing, molecular and “point-of-care” testing platforms and veterinary testing. M&A and consolidation should continue. The sector is a laggard due to slowing  sales and earnings growth vs forecasts. Rayno Clinical Diagnostics Portfolio Update We initiated coverage of Clinical Diagnostic and Life Science Tools stocks in […]

Continue Reading 0